新型肝功能评分模型在肝细胞癌射频消融治疗中的应用价值

陈敏强; 李文韬; 刘晓光; 徐浩; 陈念平

doi:10.3969/j.issn.1001-5256.2020.09.041

新型肝功能评分模型在肝细胞癌射频消融治疗中的应用价值

DOI: 10.3969/j.issn.1001-5256.2020.09.041

广东医科大学附属医院肝胆外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 446
- HTML全文浏览量: 22
- PDF下载量: 86
- 被引次数: 0
出版历程
- 出版日期: 2020-09-20

Application value of new liver function scoring models in radiofrequency ablation for hepatocellular carcinoma

Department of Hepatobiliary Surgery, The Affiliated Hospital of Guangdong Medical University

摘要

摘要:
综合评分模型是肝功能评估的主要方法之一,也是肝细胞癌治疗策略的重要组成部分。总结了传统评分模型（CTP评分及MELD评分）和新型评分模型（白蛋白-胆红素评分、血小板-白蛋白-胆红素评分、白蛋白-吲哚菁绿评分）应用于肝细胞癌射频消融治疗方面的价值与局限性,认为新型评分模型尤其是血小板-白蛋白-胆红素评分更具优势。
- 肝细胞癌 /
- 导管消融术 /
- 肝功能评分
Abstract:
Comprehensive scoring models are one of the main methods for liver function evaluation and an important part of the treatment strategy for hepatocellular carcinoma. This article summarizes the value and limitations of traditional scoring models( Child-Turcotte-Pugh score and Model for End-Stage Liver Disease score) and new scoring models( albumin-bilirubin score,platelet-albumin-bilirubin score,and albumin-indocyanine green score) in radiofrequency ablation for hepatocellular carcinoma and points out that the new scoring models,especially platelet-albumin-bilirubin score,are advantageous.
- hepatocellular carcinoma /
- catheter ablation /
- liver function score

HTML全文

参考文献(30)

[1] HO SY,LIU PH,HSU CY,et al. Prognostic performance of ten liver function models in patients with hepatocellular carcinoma undergoing radiofrequency ablation[J]. Sci Rep,2018,8(1):843.

[2] FANG KC,SU CW,CHIOU YY,et al. The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation:A propensity score matching analysis[J]. Eur Radiol,2017,27(6):2600-2609.

[3] GIORGIO A,MEROLA MG,MONTESARCHIO L,et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma in cirrhosis:Analysis of complications in a single centre over 20 years[J]. Br J Radiol,2017,90(1074):20160804.

[4] PARK JG,PARK SY,TAK WY,et al. Early complications after percutaneous radiofrequency ablation for hepatocellular carcinoma:An analysis of 1,843 ablations in 1,211 patients in a single centre:Experience over 10 years[J]. Clin Radiol,2017,72(8):692. e9-692.e15.

[5] ZHANG L,GE NL,CHEN Y,et al. Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma:10-year follow-up in Chinese patients[J]. Med Oncol,2015,32(3):77.

[6] FONSECA AZ,SAAD WA,RIBEIRO JR MA. Complications after radiofrequency ablation of 233 hepatic tumors[J]. Oncology,2015,89(6):332-336.

[7] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(2019 edition)[J]. J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2019年版)[J]．临床肝胆病杂志，2020,36(2):277-292.

[8] LEE SK,SONG MJ,KIM SH,et al. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin(PALBI)and albumin-bilirubin(ALBI)grade:A nationwide cohort study[J]. PLo S One,2019,14(5):e0216173.

[9] LIU PH,HSU CY,HSIA CY,et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era[J]. J Gastroenterol Hepatol,2017,32(4):879-886.

[10] MALINCHOC M,KAMATH PS,GORDON FD,et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology,2000,31(4):864-871.

[11] SANTAMBROGIO R,BRUNO S,KLUGER MD,et al. Laparoscopic ablation therapies or hepatic resection in cirrhotic patients with small hepatocellular carcinoma[J]. Dig Liver Dis,2016,48(2):189-196.

[12] LEE S,RHIM H,KIM YS,et al. Post-ablation des-gammacarboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma[J]. Liver Int,2016,36(4):580-587.

[13] WANG Y,JIA JD. Evaluation of liver function and general condition before ablation and principles of medical treatment[J].Natl Med J China,2015,95(27):2160-2163.(in Chinese)王宇，贾继东．消融术前肝脏功能及全身情况评估与内科治疗原则[J]．中华医学杂志，2015,95(27):2160-2163.

[14] XIA F,LAI EC,LAU WY,et al. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis Brelated small hepatocellular carcinoma[J]. Ann Surg Oncol,2012,19(4):1284-1291.

[15] QADAN M,GARDEN OJ,CORVERA CU,et al. Management of postoperative hepatic failure[J]. J Am Coll Surg,2016,222(2):195-208.

[16] JOHNSON PJ,BERHANE S,KAGEBAYASHI C,et al. Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach-the ALBI grade[J]. J Clin Oncol,2015,33(6):550-558.

[17] HIRAOKA A,KUMADA T,KUDO M,et al. Albumin-Bilirubin(ALBI)grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology:A comparison with the liver damage and Child-Pugh classifications[J]. Liver Cancer,2017,6(3):204-215.

[18] NA SK,YIM SY,SUH SJ,et al. ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma[J]. J Surg Oncol,2018,117(5):912-921.

[19] CHONG CC,CHAN AW,WONG J,et al. Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma[J]. Surgeon,2018,16(3):163-170.

[20] KAO WY,SU CW,CHIOU YY,et al. Hepatocellular carcinoma:Nomograms based on the Albumin-Bilirubin grade to assess the outcomes of radiofrequency ablation[J]. Radiology,2017,285(2):670-680.

[21] CHEN PC,CHIU NC,SU CW,et al. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy[J]. J Chin Med Assoc,2019,82(1):2-10.

[22] OH IS,SINN DH,KANG TW,et al. Liver function assessment using Albumin-Bilirubin grade for patients with very earlystage hepatocellular carcinoma treated with radiofrequency ablation[J]. Dig Dis Sci,2017,62(11):3235-3242.

[23] CHAN AW,KUMADA T,TOYODA H,et al. Integration of albumin-bilirubin(ALBI)score into Barcelona Clinic Liver Cancer(BCLC)system for hepatocellular carcinoma[J]. J Gastroenterol Hepatol,2016,31(7):1300-1306.

[24] CHAN AW,CHONG CC,MO FK,et al. Incorporating albuminbilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma[J]. J Gastroenterol Hepatol,2017,32(1):221-228.

[25] KOKUDO T,HASEGAWA K,AMIKURA K,et al. Assessment of preoperative liver function in patients with hepatocellular carcinoma-the Albumin-Indocyanine Green Evaluation(ALICE)Grade[J]. PLo S One,2016,11(7):e0159530.

[26] MIYAZAKI Y,KOKUDO T,AMIKURA K,et al. Albumin-indocyanine green evaluation grading system predicts post-hepatectomy liver failure for biliary tract cancer[J]. Dig Surg,2019,36(1):13-19.

[27] RUSSOLILLO N,FORCHINO F,CONCI S,et al. Validation of the albumin-indocyanine green evaluation model in patients with resected hepatocellular carcinoma and comparison with the albumin-bilirubin score[J]. J Hepatobiliary Pancreat Sci,2019,26(1):51-57.

[28] JARUVONGVANICH V,SEMPOKUYA T,WONG L. Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma?[J]. J Gastrointest Oncol,2018,9(4):750-761.

[29] SHIN J,YU JH,JIN YJ,et al. Effective therapeutic options for elderly patients with hepatocellular carcinoma:A nationwide cohort study[J]. Medicine(Baltimore),2019,98(30):e16150.

[30] TAKAMOTO T,SUGAWARA Y,HASHIMOTO T,et al. Evaluating the current surgical strategies for hepatocellular carcinoma[J]. Expert Rev Gastroenterol Hepatol,2016,10(3):341-357.

施引文献

资源附件(0)

访问统计